James Love's blog

Report from SCCR 22 discussions of WIPO treaty for persons who are blind or have other disabilities

WBU_IMG_0931.JPG
Members of the WBU delegation at WIPO SCCR 22

June 16, 10 am: There are good news and less good news to report from Geneva. While overall, things have moved in positive directions, with the US and the EU engaged in very constructive negotiations with Brazil and other treaty sponsors, there are still many frustrations.

White House and European Commission trade official oppose waiver of drug patents for Least Developed Countries (LDCs)

KEI Policy Brief 2011:1
June 11, 2011, Revised August 15, 2011

Pharmaceutical global R&D was 7.9 percent of sales in 2010

Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.


sales_rnd_2010_0.png
These are the data:

2010 Global R&D by all private companies: - $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile
http://report.nih.gov/investigators_and_trainees/acd_bwf/pdf/Phrma_Indus...

2010 Global sales - $856 billion

KEI Intervention at UN HLM on HIV: De-Linking R&D costs from drug prices and the sustainability of treatment

un_hlm_panel_3_IMG_2446.JPGThese are the notes from my intervention today at the UN's High Level Meeting on HIV/AIDS in New York. The persons making statements from the floor were asked to keep their comments to two minutes, so the actual intervention was somewhat shorter. Jamie

2011 High-Level Meeting on
the comprehensive review of the progress achieved in realizing
the Declaration of Commitment on HIV/AIDS and

Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries

KEI has received a copy of a May 16, 2011 letter from Karl De Gucht to Andris Piebalgs, which discusses (1) the EU-India FTA, and (2) Relations between IPR and development policies.

Senator Sanders introduces two medical innovation prize bills in U.S. Senate to de-link R&D costs from drug prices

Sanders_IMG_3442.jpgOn Thursday, May 26, 2011, Senator Bernie Sanders (I-VT) introduced two bills in the United States Senate that would de-link R&D costs from drug prices. The bill names and numbers are as follows:

  • The Medical Innovation Prize Fund Act: S. 1137
  • The Prize Fund for HIV/AIDS Act: S. 1138

USPTO statement at WIPO side event on Medicines Patent Pool

This is the statement that was delivered by Karin L. Ferriter (from USPTO and USTR), at a UNITAID side event on the Medicines Patent Pool, during a break of the WIPO Standing Committee on the Law of Patents.

Statement on Medicines Patent Pool Side Event

NGO Statement on WHO governance and the Management of Conflicts of Interest and the Future of Financing for WHO

NGO Statement on WHO governance and the Management of Conflicts of Interest and the Future of Financing for WHO.

May 18, 2011

We write to express our concerns about governance of the World Health Organization (WHO) and other public health bodies, as regards the management of conflicts of interest.

KEI comments to the WIPO patent committee discussion of patent quality

During today's discussion at the WIPO Standing Committee on the Law of Patents (SCP) on patent quality KEI make four points in its intervention.

1. WIPO should consider gathering information on the costs of litigation to challenge the validity of patents.

2. WIPO should consider creating a database to share information on the cases where litigation has resulted findings that patent claims as invalid.

Dr. Balasubramaniam

On April 19, 2011, Dr Kumariah Balasubramaniam died at his home in Sri Lanka. Dr. Balasubramaniam, known to many as Dr. Bala, was described by Professor Colvin Gooneratne as "one of the most knowledgeable, resolute, articulate, versatile, resilient and in many other ways exceptionally brilliant health activists [the world] has produced." My tribute to Dr. Bala is in the Huffington Post. Prof.

The USTR Special 301 Report, some initial reactions

The USTR Special 301 Report was issued today. The full report is here, the USTR web page on the report is here, and a link to the USTR press release about the report is here.

Senator Wyden releases redacted version of October 29, 2010 CRS report on ACTA

On April 26, 2011, Senator Wyden released a redacted version of the Congressional Research Service (CRS) report on ACTA that has been the subject to an ongoing Freedom of Information ACT (FOIA) dispute with USTR.

(More context here, here and here).

This is a link to the report that USTR claimed they could not release because of restrictions on its use by Senator Wyden.

http://keionline.org/sites/default/files/RedactedACTACRSMemotoSenWyden.pdf

Homeland Security's 2008 letter to USTR: ACTA is a threat to national security

On August 7, 2008, Stewart Baker, the Assistant Secretary for Policy at the Department of Homeland Security, sent a one page letter and a three page "Policy Position on Border Measures of the Anti-Counterfeiting Trade Agreement."

Stewart Baker was the General Counsel of the National Security Agency from 1992 to 1994, and was appointed the first Assistant Secretary for Policy at the Department of Homeland Security (DHS) by George W Bush.

White House rejects administrative appeal on FOIA request for CRS study of ACTA

KEI just received the attached letter from the Executive Office of the President's Office of the United States Trade Representative (USTR) rejecting our appeal of USTRs decision to withhold a study by the Library of Congress' Congressional Research Service on ACTA that was done for Senator Wyden.

http://keionline.org/sites/default/files/USTR_20April2011_FOIA_APPEAL--CaseFile_no_10101455.pdf

Syndicate content